The Future of HIV-1 Therapeutics
Resistance Is Futile?
Buch in deiner Nähe kaufen
Beschreibung
This volume thoroughly covers HIV-1 antiretrovirals currently in clinical use, together with their advantages and limitations. HIV-1 inhibitor resistance is discussed in detail, and critical assessments as to what will be required of future antiretrovirals in order to halt viral replication, reduce viral resistance, and alter the state of viral latency are presented. Experts at the forefront of HIV-1 research provide overviews of approaches from the fields of virology, chemical biology and structural biology for obtaining small molecule inhibitors that target viral regulatory and structural components at multiple points in the viral lifecycle. The individual chapters will appeal to scientists and clinicians alike.
Highlights the identification and evaluation of antiretrovirals that may be less prone in selecting for HIV-1 resistance Covers recent advances in the identification and function of small molecule inhibitors that target novel HIV-1 regulatory and structural components to disrupt replication and alter the state of viral latency Offers up-to-date information for virologists, infectious disease specialists, and chemical biologists on HIV-1 antiretrovirals currently in use Includes supplementary material: sn.pub/extras
Autor*in
Bruce E. Torbett
Themen in »The Future of HIV-1 Therapeutics«
Fragment-based drug design HIV Gag protein HIV capsid HIV integrase protein HIV matrix HIV nucleocapsid protein HIV protease HIV reverse transcriptase protein HIV stem-loop HIV transcription HIV-1 antiretroviral treatment HIV-1 drug resistance HIV-1 illustrations HIV-1 latency High-throughput virtual screening
Stimmen zu »The Future of HIV-1 Therapeutics«
“The book does a fantastic job of addressing new approaches to inhibit HIV-1. … this is a useful book that can be used by researchers, HIV clinicians, and medicinal chemists interested in investigating new molecules for the treatment of HIV-1. It addresses novel areas that have no chemical entities that are FDA approved. There are no books that compete with this one.” (Christopher J. Destache, Doody's Book Reviews, September, 2015)
“This book includes 8 comprehensive, heavily referenced chapters on antiretroviral drug development. … a comprehensive, readable review of a subject that brings together 2 or more decades of molecular virology research and drug development. … the chapters in this book are likely to be, for the next several years, highly useful and popular starting points for learning about new areas in HIV drug development.” (Robert W. Shafer, Clinical Infectious Diseases, September, 2015)
()